首页> Expert review of respiratory medicine> First-line immunotherapy in non-small cell lung cancer: how to select and where to go.

First-line immunotherapy in non-small cell lung cancer: how to select and where to go.

导出 LinkOut

翻译打印收藏纠错

第一作者： Andrea,Mogavero

第一单位： Department of Oncology, University of Turin, Turin, Italy.

作者： Andrea,Mogavero ^[1] ; Ornella,Cantale ^[1] ; Veronica,Mollica ^[2] ; Shobana,Anpalakhan ^[3] ; Alfredo,Addeo ^[4] ; Giannis,Mountzios ^[5] ; Alex,Friedlaender ^[6] ; Ravindran,Kanesvaran ^[7] ; Silvia,Novello ^[1] ; Giuseppe Luigi,Banna ^[8]

作者单位： Department of Oncology, University of Turin, Turin, Italy. ^[1] Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. ^[2] Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK. ^[3] Oncology Department, HUG-Hopitaux Universitaires de Geneve, Geneva, Switzerland. ^[4] Fourth Oncology Department and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece. ^[5] Oncology Department, University Hospital, Geneva, Switzerland. ^[6] Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.;SingHealth Duke-NUS Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore, Singapore. ^[7] Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.;Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK. ^[8]

关键词 ICIS LAG3 NSCLC TIGIT acquired resistance oncogene addicted predictive factors primary resistance

医学主题词人类(Humans);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);肺肿瘤(Lung Neoplasms);免疫疗法(Immunotherapy);病人遴选(Patient Selection)

DOI 10.1080/17476348.2024.2302356

PMID 38294292

发布时间 2025-09-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交